IN MATRICO™ Drug Discovery
Increasing predictiveness and confidence in drug discovery
for cancer, fibrosis, and other devastating diseases.

News
Xylyx Bio and Cell&Soft Announce positive initial results following Strategic Partnership to Develop Next-Generation in vitro Platforms to Accelerate Cancer Drug Discovery
New York-based Xylyx Bio, a leader in predictive disease models and tissue-specific extracellular matrix (ECM) products, and Cell&Soft SAS, a French biotech company specializing in innovative soft cell culture plates, today announced positive preliminary results, reaching a key milestone in their partnership to develop more physiologically relevant in vitro cellular models for cell-based assays in oncology.
Read MoreXYLYX BIO launches specialized contract R&D services that increase predictiveness in antifibrotic drug discovery
Xylyx Bio now offers specialized contract R&D services based on its highly predictive IN MATRICO™ platform. Xylyx Bio’s custom assays incorporate human disease-specific extracellular matrix (ECM) substrates combined with clinically relevant informatics to better represent human biology and reliably de-risk drug discovery through early efficacy signals that simultaneously reduce costs and development time.
Read MoreXYLYX BIO releases highly physiologic 2D substrates for improved antifibrotic drug discovery
Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH.
Read MoreXylyx Bio and Cell&Soft Announce Strategic Partnership to Develop Next-Generation Cell Culture Platforms to Accelerate Cancer Drug Discovery
New York-based Xylyx Bio, a leader in predictive disease models and tissue-specific extracellular matrix (ECM) products, and Cell&Soft SAS, a French biotech company specializing in innovative soft cell culture plates,today announced a strategic partnership for the development of in vitro cellular models for cell-based assays in oncology.
Read More